Pharmaceutical Company
Appears in 1 story
First-mover in Indian generic semaglutide market
Only 200,000 of India's roughly 250 million people living with obesity have ever taken a GLP-1 receptor agonist—the class of drugs that includes Novo Nordisk's blockbuster Ozempic and Wegovy. On March 21, the day after Novo's last Indian patent expired, more than 40 companies began selling generic semaglutide at prices as low as 1,290 rupees a month—about $15, compared to $100-175 for the branded versions. It is the largest single-day generic launch in Indian pharmaceutical history.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
